{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:28:05Z","timestamp":1787308085772,"version":"build-2736575974"},"reference-count":15,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Evidence regarding predictors of pathological response and long-term outcomes in older patients receiving perioperative FLOT chemotherapy for resectable gastric or gastroesophageal junction cancer remains limited. We aimed to identify factors associated with pathological response and survival in patients aged \u226565 years treated with neoadjuvant FLOT. Materials and Methods: This retrospective single-center study included 86 consecutive patients (median age, 69 years; 72.1% male) aged \u226565 years with resectable gastric or gastroesophageal junction adenocarcinoma who underwent neoadjuvant FLOT chemotherapy followed by curative-intent gastrectomy. Major pathological response was defined as College of American Pathologists tumor regression grade (CAP TRG) 0\u20131. Logistic regression analyses were performed to identify predictors of pathological response. Disease-free survival (DFS) and overall survival (OS) were analyzed using the Kaplan\u2013Meier method and Cox proportional hazards regression analyses. Results: Overall, 14 patients (16.3%) achieved a major pathological response. Body mass index (BMI) \u2265 25 kg\/m2 (OR 5.13, p = 0.04) was independently associated with a major pathological response. During a median follow-up of 29.2 months, 39 patients (45.3%) developed recurrence and 35 (40.7%) died. ECOG performance status (ECOG PS) \u2265 1 was independently associated with both inferior DFS (HR = 2.76, p = 0.02) and OS (HR = 2.52, p = 0.045). In addition, ypN stage 2\u20133 (HR = 2.58, p = 0.008) was independently associated with worse DFS, whereas positive surgical margins were independently associated with worse OS (HR = 2.62, p = 0.02). Conclusions: In older patients with resectable gastric or gastroesophageal junction adenocarcinoma treated with perioperative FLOT chemotherapy, baseline BMI was independently associated with major pathological response, whereas ECOG PS and postoperative pathological factors were independently associated with survival. These findings highlight the importance of careful patient selection and individualized multimodal treatment in this population.<\/jats:p>","DOI":"10.3390\/medicina62081612","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:31:59Z","timestamp":1787304719000},"page":"1612","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological Predictors of Pathological Response and Survival in Older Patients Undergoing Perioperative FLOT Chemotherapy for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4312-724X","authenticated-orcid":false,"given":"Aykut","family":"\u00d6zmen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital, 34480 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuba","family":"Tahtal\u0131","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital, 34480 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnd\u00fcz","family":"Karao\u011flan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital, 34480 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Kutlay","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital, 34480 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3970-4780","authenticated-orcid":false,"given":"Ulviye","family":"Oflas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital, 34480 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9381-1934","authenticated-orcid":false,"given":"Tanju","family":"Kapa\u011fan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital, 34480 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nil\u00fcfer","family":"Bulut","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital, 34480 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3375-9465","authenticated-orcid":false,"given":"G\u00f6kmen Umut","family":"Erdem","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital, 34480 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2\/3 trial","volume":"393","author":"Homann","year":"2019","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103657","DOI":"10.1016\/j.esmoop.2024.103657","article-title":"Adequate assessment yields appropriate care-the role of geriatric assessment and management in older adults with cancer: A position paper from the ESMO\/SIOG Cancer in the Elderly Working Group","volume":"9","author":"Loh","year":"2024","journal-title":"ESMO Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9401","DOI":"10.1002\/cam4.5701","article-title":"Lymphovascular or perineural invasion is associated with lymph node metastasis and survival outcomes in patients with gastric cancer","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med."},{"key":"ref_7","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Xie, J.W., Lu, J., Xu, B.B., Zheng, C.H., Li, P., Wang, J.B., Lin, J.X., Chen, Q.Y., Cao, L.L., and Lin, M. (2021). Prognostic Value of Tumor Regression Grading in Patients Treated with Neoadjuvant Chemotherapy Plus Surgery for Gastric Cancer. Front Oncol., 11.","DOI":"10.3389\/fonc.2021.587856"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/jamaoncol.2021.0848","article-title":"Efficacy of Reduced-Intensity Chemotherapy with Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients with Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial","volume":"7","author":"Hall","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ejca.2012.09.025","article-title":"The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)","volume":"49","author":"Pauligk","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10120-023-01404-2","article-title":"Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: A population-based cohort study","volume":"26","author":"Keywani","year":"2023","journal-title":"Gastric Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5230\/jgc.2017.17.e8","article-title":"Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer","volume":"17","author":"Palmela","year":"2017","journal-title":"J. Gastric Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Correia, M., Moreira, I., Cabral, S., Castro, C., Cruz, A., Magalh\u00e3es, B., Santos, L.L., and Irving, S.C. (2023). Neoadjuvant Gastric Cancer Treatment and Associated Nutritional Critical Domains for the Optimization of Care Pathways: A Systematic Review. Nutrients, 15.","DOI":"10.3390\/nu15102241"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/SLA.0b013e318216f449","article-title":"Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: A summary of 480 cases","volume":"253","author":"Becker","year":"2011","journal-title":"Ann. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Association (2023). Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer, 26, 1\u201325.","DOI":"10.1007\/s10120-022-01331-8"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1612\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:03:06Z","timestamp":1787306586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["medicina62081612"],"URL":"https:\/\/doi.org\/10.3390\/medicina62081612","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}